BioInvent International AB (publ)
BOVNF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$29.18M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $29.18 Million |
|---|---|
| Enterprise Value | $-253,392,404.00 |
| Earnings per Share | $-5.07 |
| Beta | 0.02 |
| Outstanding Shares | 65,697,238 |
Return
| Return on Equity | -154.86% |
|---|---|
| Return on Assets | -115.92% |
| Return on Invested Capital | -150.55% |
Valuation & Multiples
| P/E Ratio | -0.73 |
|---|---|
| PEG | 10.33 |
| Price to Sales | - |
| Price to Book Ratio | 0.11 |
| Enterprise Value to Revenue | 54.74 |
| Enterprise Value to EBIT | -4.44 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 29, 2026
EPS Estimate
$-0.20
Consensus analyst estimateRevenue Estimate
$796,855
Consensus analyst estimateNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
$-0.17
Consensus analyst estimateRevenue Estimate
$932,738
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About BioInvent International AB (publ)
108 employees
CEO: Martin Welschof
BioInvent International AB (publ) is a clinical-stage Swedish company dedicated to discovering, researching, and developing immunomodulatory antibodies for global cancer treatment, with reach across Sweden, Europe, the United States, and...